ESSR 2019 / P-0090
Gadolinium use in musculoskeletal Imaging - is it time to rethink? A survey of British and International Musculoskeletal Radiologists.
Keywords:
Musculoskeletal system, MR, Contrast agent-intravenous, Safety, Education and training
Authors:
A. Shah1, R. Botchu2; 1Leicester/UK, 2Birmingham/UK
DOI:
10.26044/essr2019/P-0090
References
- Carr DH,
Brown J,
Bydder GM et al.
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
AJR Am J Roentgenol 1984;143(2): 215–24.
- Lohrke J,
Frenzel T,
Endrikat J et al.
25 years of contrast-enhanced MRI: Developments,
current challenges and future perspectives.
Adv Ther 2016; 33(1): 1–28.
- Kanda T,
Fukusato T,
Matsuda M et al.
Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy.
Radiology 2015; 276(1): 228–232.
- Welk B,
McArthur E,
Morrow SA et al.
Association between gadolinium contrast exposure and the risk of parkinsonism.
JAMA 2016; 316(1): 96–98.